The biopharmaceutical company Pfizer Mexico announced its commitment to the public health of the country and its goal to reach 18 million people by 2030. At the event "Innovating for a Healthier 2025," the company highlighted the importance of collaboration between the public and private sectors for the future of health in Mexico.
During the conference, the need to integrate scientific advances, education, and solid public policies was emphasized to ensure equitable access to quality services in the Mexican healthcare system. Pfizer committed to working on strategic alliances and consolidated purchases to improve the distribution of treatments in vulnerable areas and ensure that no patient is left behind.
The president and CEO of Pfizer Mexico, Juan Luis Morell, underscored the importance of collaborating with government authorities to build a more inclusive and efficient healthcare system. Dr. Yéssika Moreno, Director of Medical Affairs, highlighted the relevance of clinical research in the company's plans towards 2030, where equity and access are fundamental.
It was mentioned that clinical research is essential for developing innovative treatments and improving access to high-quality therapeutic options. In particular, messenger RNA was highlighted as a revolutionary technology that has enabled the faster development of vaccines and personalized treatments for various diseases.
Pfizer Mexico projects a double-digit growth for 2025, supported by its capacity for innovation and adaptability to the market. With these initiatives, the company positions itself as a strategic ally in building a stronger healthcare system that can meet the present and future needs of the Mexican population.
